natgillin/translations-raw huggingface dataset:
The main limitations in the dataset arise from the limited number of patients by arm (which hinder the interpretability of the study results), and from the duration of the placebo-controlled phase (6 months).
Glavne omejitve nabora podatkov so povezane z omejenim številom bolnikov v posameznem kraku (kar ovira razlago rezultatov študije) in trajanjem s placebom nadzorovane faze (šest mesecev).
Other findings already seen for other antisense oligonucleotides, like elevation of transaminases have also been identified.
Ugotovljene so bile tudi druge nepravilnosti, ki so bile opažene tudi pri drugih protismiselnih oligonukleotidih, npr. zvišanje ravni transaminaz.
The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the proposed SmPC.
Kakovost zdravila Exondys je bila ocenjena za sprejemljivo, če se zdravilo uporablja skladno s pogoji, opredeljenimi v predlaganem povzetku glavnih značilnosti zdravila.
Although the evidence of truncated dystrophin production may support the mechanism of action of the product, convincing demonstration of sustained functional effect is necessary to support the claim for efficacy of the medicinal product in the intended indication.
Čeprav bi lahko dokaz tvorbe skrajšanega distrofina podprl mehanizem delovanja zdravila, je treba za podprtje trditve o učinkovitosti zdravila pri izbrani indikaciji prepričljivo dokazati njegov dolgotrajni funkcionalni učinek;
The CHMP considered that with the currently available data it is not possible to conclude that the benefit/risk balance of eteplirsen is positive in DMD patients with mutations amenable to exon 51 skipping, since:
Odbor CHMP je menil, da na podlagi trenutno razpoložljivih podatkov ni mogoče zaključiti, da je razmerje med koristmi in tveganji eteplirsena pri bolnikih z DMD z mutacijami, odzivnimi na preskok eksona 51, pozitivno, saj:
Comparison with untreated patients is challenging as only 4 patients were on placebo for 24 weeks.
Primerjavo z nezdravljenimi bolniki je težko narediti, saj so bili 24 tednov s placebom zdravljeni le štirje bolniki.
There are no comparative data with patients on placebo beyond 24 weeks, and the available data for patients on treatment are derived from only a limited number of patients (n=12).
Primerjalni podatki za bolnike, ki so bili zdravljeni s placebom dlje kot 24 tednov, niso na voljo, za zdravljene bolnike pa so podatki na voljo samo za omejeno število bolnikov (n = 12).
The limitation derived from the small numbers is acknowledged, but the fact that it is a result of the small number of patients does not reduce the uncertainty related to the results observed.
Čeprav je bila upoštevana omejitev zaradi majhnega števila vključenih bolnikov, se zaradi dejstva, da gre za majhno število bolnikov, nezanesljivost opazovanih izidov ne zmanjša.
The limitation of the database size does not allow for the identification of frequent AEs (≥10%) and the lack of a comparator placebo arm makes it impossible to distinguish between AEs related to the disease or the age of the population and those related to the drug.
Zaradi omejene velikosti podatkovnih zbirk ni mogoče prepoznati pogostih neželenih učinkov (≥ 10 %), pomanjkanje primerjalnega kraka s placebom zdravljenih bolnikov pa onemogoča razlikovanje med neželenimi učinki, povezanimi z boleznijo ali starostjo populacije, in tistimi, ki so povezani z zdravilom.
In conclusion, the safety profile of eteplirsen has not been thoroughly characterized.
Zaključiti je mogoče, da varnostni profil eteplirsena ni popolnoma določen.
For this application clinical data were provided from a randomized, double-blinded, placebo controlled 24week Phase IIb study (study 201) and its open label extension Study 202 in a total of 12 DMD patients.
Klinični podatki za to vlogo so bili pridobljeni iz randomizirane, dvojno slepe, s placebom nadzorovane 24-tedenske študije faze IIb (študije 201) in njene odprte podaljšane študije 202 s skupno 12 bolniki z Duchennovo mišično distrofijo (DMD).
Additional post-hoc comparisons with other external controls also have their limitations, as previously mentioned.
Kot omenjeno, dodatno omejitev pomenijo tudi naknadne primerjave z drugimi zunanjimi kontrolnimi skupinami.
Longer comparisons (up to 4 years) with 12 DMD patients on eteplirsen were subsequently performed versus two post-hoc defined, external and non-concurrent cohorts (Italian Telethon DMD Registry and Leuven Neuromuscular Reference Center Registry) in an open label extension study.
Nato so bile v odprti podaljšani študiji opravljene daljše (do štiriletne) primerjave med zdravljenjem 12 bolnikov z DMD, ki so prejemali eteplirsen, in zdravljenjem dveh naknadno opredeljenih, zunanjih in nesočasnih kohort (italijanskega registra bolnikov z DMD fundacije Telethon in registra referenčnega centra za živčno-mišične bolezni v Leuvnu).
This increases the uncertainty about the reliability of such comparisons rather than providing confirmatory data for efficacy.
Tovrstni podatki povečujejo dvom o zanesljivosti primerjav in ne potrjujejo njihove učinkovitosti;
The primary analysis of this pivotal trial provided a 24-week comparison of only 4 patients on eteplirsen exposed to the proposed dose of 30mg/kg/week versus placebo (n=4), and additionally 4 patients exposed to 50 mg/kg/week, in which no difference was observed in the 6MWD.
Primarna analiza tega ključnega preskušanja je omogočila 24-tedensko primerjavo med samo štirimi bolniki, zdravljenimi z eteplirsenom v predlaganem odmerku 30 mg/kg/teden, in bolniki (n = 4), zdravljenimi s placebom, in naknadno še štirimi bolniki, izpostavljenimi odmerku 50 mg/kg/teden, pri katerih pri šestminutnem preizkusu hoje ni bila opažena nobena razlika.
The comparison was done with an untreated control arm of DMD patients amenable to exon skipping of an exon other than exon 51.
Primerjava je bila opravljena z nezdravljenim kontrolnim krakom bolnikov z DMD, dovzetnih za preskok eksona, ki ni ekson 51.
The only comparative data comes from study 201 (n=12) in which 4 subjects were randomized to 30 mg/kg, 4 to 50 mg/kg and 4 to placebo for 24 weeks.
Edini primerjalni podatki izhajajo iz študije 201 (n = 12), pri kateri so bili 24 tednov štirje bolniki randomizirani na 30 mg/kg, štirje na 50 mg/kg in štirje na placebo.
A trend favouring eteplirsen treated patients was observed in loss of ambulation (2/12 in eteplirsen treated patients vs. 10/13 in external controls at Year 4), North Star Ambulatory Assessment and ability to rise from supine.
Gibanje v korist bolnikov, zdravljenih z eteplirsenom, je bilo vidno pri krajši prehojeni razdalji (v četrtem letu pri 2 bolnikih od 12, zdravljenih z eteplirsenom, in pri 10 bolnikih od 13 iz zunanjih kontrolnih skupin), oceni gibanja po lestvici North Star in sposobnosti bolnika za dvig iz ležečega položaja.
For the long-term safety assessment, safety data are available only for a small set of patients (6 on eteplirsen 30 mg/kg and 6 on 50 mg/kg).
Varnostni podatki za oceno dolgoročne varnosti so na voljo samo za majhno podskupino bolnikov (šest bolnikov, zdravljenih s 30 mg/kg eteplirsena, in šest bolnikov, zdravljenih s 50 mg/kg eteplirsena).
There are data available from the extension study 202 in which only 6 patients were treated with eteplirsen, 30 mg/kg and 6 with eteplirsen 50 mg/kg for approximately 3 additional years.
Na voljo so podatki iz podaljšane študije 202, v kateri so približno tri dodatna leta samo šest bolnikov zdravili s 30 mg/kg eteplirsena in šest bolnikov s 50 mg/kg eteplirsena.
A comparison versus a different external and non-concurrent cohort was provided (DMD patients on placebo from the pivotal trial of another medicinal product) for both the whole population and that restricted to those DMD patients walking between 300 and 450 m., and similar shortcomings regarding the comparison groups were identified there.
Za celotno populacijo in populacijo bolnikov z DMD, ki lahko prehodijo od 300 do 450 m, je bila predložena primerjava z različno zunanjo in nesočasno kohorto (bolniki z DMD, zdravljeni s placebom, iz ključnega preskušanja drugega zdravila), tam pa so bile ugotovljene podobne pomanjkljivosti glede primerjalnih skupin.
There was no difference in 6MWD between eteplirsen and placebo during this 24 week treatment period.
Pri šestminutnem preizkusu hoje v 24-tedenskem obdobju zdravljenja ni bilo razlike med eteplirsenom in placebom;
One myocardytis event with an atypical presentation was identified in one patient on eteplirsen 30 mg/kg.
Pri enem bolniku, zdravljenem s 30 mg/kg eteplirsena, je bila prepoznana ena epizoda miokarditisa z atipično klinično sliko.
Interim analysis became available for one of them, the PROMOVI (study 301) an open-label, multicentre study performed in DMD patients with genetically confirmed DMD with exon deletions amenable to exon 51 skipping.
Pri eni izmed njih - odprti, multicentrični študiji PROMOVI (študija 301), ki je bila izvedena z bolniki z genetsko potrjeno DMD z delecijami eksonov, dovzetnimi za preskok eksona 51 -, je bila predložena vmesna analiza.
The lack of a placebo controlled arm prevent from drawing any conclusions.
Ker kontrolnega kraka s placebom zdravljenih bolnikov ni bilo, ni mogoče oblikovati nobenega sklepa.
All patients (100%) included in the pivotal trial and around 50% of all patients treated with any dose of eteplirsen reported AEs, mainly hypokaliemia, dermatitis contact, oropharyngeal pain, procedural pain, vomiting, balance disorder and cough.
O neželenih učinkih, predvsem hipokaliemiji, kontaktnem dermatitisu, orofaringealni bolečini, bolečini pri posegu, bruhanju, motnjah ravnotežja in kašlju, so poročali vsi (100 %) bolniki, vključeni v ključno preskušanje, in približno 50 % vseh bolnikov, zdravljenih s katerim koli odmerkom eteplirsena.
A more pronounced deterioration was observed in the external control groups (both the amenable to exon 51 skipping control group and the one including amenable to any exon skipping patients) than in eteplirsen treated patients.
V zunanjih kontrolnih skupinah (pri kontrolni skupini, dovzetni za preskok eksona 51, in tudi pri skupini z bolniki, dovzetnimi za kakršen koli preskok eksona) je bilo opaženo izrazitejše poslabšanje kot pri bolnikih, zdravljenih z eteplirsenom.
There were no significant differences in the clinical endpoints between eteplirsen treated and untreated patients.
Med bolniki, zdravljenimi z eteplirsenom, in nezdravljenimi bolniki ni bilo razlike v kliničnih opazovanih dogodkih.
Both groups (eteplirsen treated patients and untreated external controls) experienced a decline in ambulation.
Prehojena razdalja se je skrajšala pri obeh skupinah (bolnikih, zdravljenih z eteplirsenom, in nezdravljenih zunanjih kontrolnih skupinah).
The vaccine efficacy was found to be 84%.
Učinkovitost cepiva je bila 84-%.
Frequencies per dose are defined as follows:
Pogostnost na odmerek je definirana kot:
4.7 Effects on ability to drive and use machines Not relevant.
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Podatek ni potreben.
• your child has an undiagnosed or progressive disease of the brain or epilepsy which is not controlled.
• ima vaš otrok nediagnosticirano ali napredujočo bolezen možganov ali epilepsijo, ki ni nadzorovana.
≥ 30 IU ≥ 40 IU
≥ 30 i.e. ≥ 40 i.e.
Date of latest renewal: 23 October 2005
Datum zadnjega podaljšanja dovoljenja za promet: 23. oktober 2005
Upon removal from the refrigerator, the vaccine is stable for 8 hours at 21°C.
Ko vzamemo cepivo iz hladilnika, je stabilno 8 ur pri temperaturi 21 ºC.
† cut-off accepted as indicative of protection
† mejna vrednost je sprejeta kot kazalnik zaščite
Please tell your doctor if your child has had an allergic reaction to these ingredients.
Obvestite svojega zdravnika, če je vaš otrok imel alergično reakcijo na ti sestavini.
These measures will help to protect the not less than 30 IU not less than 40 IU
Takšni ukrepi pomagajo varovati ne manj kot 30 i.e. ne manj kot 40 i.e.
• your child has a severe infection with a high temperature (over 38°C).
• ima hudo okužbo z zvišano telesno temperaturo (nad 38 ºC).
The MAH must ensure that the system of pharmacovigilance, as described in version 3.06 presented in Module 1.8.1. of the Marketing Authorisation, is in place and functioning before and whilst the product is on the market.
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, kot je opisan v različici 3,06 in predložen v modulu 1.8.1 vloge za pridobitev dovoljenja za promet z zdravilom, vzpostavljen in da deluje, preden da zdravilo v promet in ves čas trženja zdravila.
not less than 30 IU not less than 40 IU
ne manj kot 30 i.e. ne manj kot 40 i.e.
• This vaccine has been prescribed for your child. Do not pass it on to others.
• Cepivo je bilo predpisano vašemu otroku in ga ne smete dajati drugim.
As the benefit of the vaccination is high in this group of infants, vaccination should not be withheld or
Ker je korist cepljenja v tej skupini otrok velika, cepljenja ne bi smeli odložiti ali ga izpustiti.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 23 October 2000
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 23. oktober 2000
• temporarily stopping breathing (apnoea)
• začasna prekinitev dihanja (apneja),
EU/1/00/153/001 - 1 pre-filled syringe without needle EU/1/00/153/002 - 10 pre-filled syringes without needles EU/1/00/153/003 - 20 pre-filled syringes without needles EU/1/00/153/004 - 50 pre-filled syringes without needles EU/1/00/153/005 - 1 pre-filled syringe with 1 needle EU/1/00/153/006 - 10 pre-filled syringes with 10 needles EU/1/00/153/007 - 20 pre-filled syringes with 20 needles EU/1/00/153/008 - 50 pre-filled syringes with 50 needles EU/1/00/153/009 - 1 pre-filled syringe with 2 needles EU/1/00/153/010 - 10 pre-filled syringes with 20 needles
EU/1/00/153/001 - 1 napolnjena injekcijska brizga brez igle EU/1/00/153/002 - 10 napolnjenih injekcijskih brizg brez igel EU/1/00/153/003 - 20 napolnjenih injekcijskih brizg brez igel EU/1/00/153/004 - 50 napolnjenih injekcijskih brizg brez igel EU/1/00/153/005 - 1 napolnjena injekcijska brizga z 1 iglo EU/1/00/153/006 - 10 napolnjenih injekcijskih brizg z 10 iglami EU/1/00/153/007 - 20 napolnjenih injekcijskih brizg z 20 iglami EU/1/00/153/008 - 50 napolnjenih injekcijskih brizg s 50 iglami EU/1/00/153/009 - 1 napolnjena injekcijska brizga z 2 iglama EU/1/00/153/010 - 10 napolnjenih injekcijskih brizg z 2 iglama
Please tell your doctor if your child is taking or has recently taken any other medicines, including medicines obtained without a prescription or has recently had any other vaccine.
Obvestite svojega zdravnika, če vaš otrok jemlje ali je pred kratkim jemal katerokoli zdravilo, tudi če ste ga dobili brez recepta ali če je vaš otrok pred kratkim bil cepljen s katerim koli drugim cepivom.
- Tabulated summary of adverse reactions (clinical trials):
- Povzetek neželenih učinkov v preglednici (klinična preskušanja):
• Do not freeze.
Ne zamrzujte.
• Temperature of ≥ 40.0 C within 48 hours, not due to another identifiable cause;
• Zvišana telesna temperatura ≥ 40,0 ºC v 48 urah, ki ji ni možno pripisati drugega vzroka.
- a prospective blinded household contact study performed in Germany (3, 4, 5 months schedule).
- prospektivni slepi kontaktni študiji v gospodinjstvih, ki je bila izvedena v Nemčiji (cepljenje pri 3, 4 in 5 mesecih).
• Tetanus - tetanus bacteria enter the body through cuts, scratches or wounds in the skin.
• Tetanus - bakterije tetanusa pridejo v telo skozi vreznine, praske ali rane na koži.
If your child misses a dose
Če vaš otrok izpusti odmerek
The causal relationship to the vaccine has not been established.
Vzročna povezava s cepivom ni bila ugotovljena.
months N= 1146)
mesecev n = 1146)
• Hepatitis B - is caused by the hepatitis B virus.
• Hepatitis B - povzroča ga virus hepatitisa B, ki povzroči oteklino jeter.
• Diphtheria - a serious bacterial infection that mainly affects the airways and sometimes the skin.
• Davica - resna bakterijska okužba, ki v glavnem prizadene dihalne poti in občasno kožo.
Booster doses should be given in accordance with the official recommendations.
Cepljenje z obnovitvenim odmerkom je treba opraviti v skladu z uradnimi priporočili.
However, it can be expected that hepatitis D will be prevented by immunisation as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.
Vendar je mogoče pričakovati, da bo cepljenje preprečilo hepatitis D, kajti hepatitis D (ki ga povzroča agens delta) se ne pojavi, če ni okužbe s hepatitisom B.
- a NIH sponsored efficacy study performed in Italy (2, 4, 6 months schedule).
- študiji učinkovitosti, sponzorirani s strani NIH, ki je bila izvedena v Italiji (cepljenje pri 2, 4 in 6 mesecih).
• Infanrix Penta helps your child's body make its own protection (antibodies).
• Cepivo Infanrix Penta pomaga telesu vašega otroka ustvariti lastno zaščito (protitelesa).
Very common: crying abnormal, irritability, restlessness Uncommon: nervousness
Zelo pogosti:nenormalen jok, razdražljivost, nemirnost Občasni: živčnost
Medium 199 containing principally amino acids, mineral salts, vitamins
medij 199, ki vsebuje predvsem aminokisline, mineralne soli, vitamine
• Your child will have a total of two or three injections with at least 1 month between each injection.
• Vaš otrok bo prejel skupaj dva ali tri odmerke cepiva z vsaj enomesečnim presledkom med odmerki.
Locally established immunoprophylactic measures against hepatitis B should be maintained.
Treba je upoštevati predpisane lokalne imunoprofilaktične ukrepe proti hepatitisu B.
• Medicines should not be disposed of via wastewater or household waste.
• Cepiva ne smete odvreči v odpadne vode ali med gospodinjske odpadke.
• As with all vaccines, Infanrix Penta may not fully protect all children who are vaccinated.
• Tako kot velja za vsa cepiva, cepivo Infanrix Penta morda ne bo popolnoma zaščitilo vseh cepljenih otrok.
Allergic reactions, including anaphylactic and anaphylactoid reactions
Alergijske reakcije, vključno z anafilaktičnimi in anafilaktoidnimi reakcijami
In extremely rare cases, paralysis, neuropathy, Guillain-Barré syndrome, encephalopathy, encephalitis and meningitis have been reported.
V izjemno redkih primerih so poročali o primerih paralize, nevropatije, Guillain-Barréjevem sindromu, encefalopatiji, encefalitisu in meningitisu.
months N= 884
mesecev n = 884
A minor infection such as a cold should not be a problem, but talk to your doctor first.
Blažja okužba kot je na primer prehlad, ne bi smela biti težava, vendar se pred cepljenjem vseeno
However, sometimes it can be very serious and cause permanent damage or even death.
Včasih pa je lahko zelo resna in povzroči trajne poškodbe alicelo smrt.
As Infanrix Penta is not intended for use in adults, adequate human data on use during pregnancy or lactation and adequate animal reproduction studies are not available.
Ker cepivo Infanrix Penta ni predvideno za uporabo pri odraslih, ni podatkov o uporabi med nosečnostjo in dojenjem, prav tako ni na voljo ustreznih študij o vplivu na razmnoževanje pri živalih.
The syringe should be well shaken in order to obtain a homogeneous turbid white suspension.
Brizgo je potrebno dobro pretresti, da nastane homogena motna bela suspenzija.
In a follow-up of the same cohort, the efficacy was confirmed up to 60 months after completion of primary vaccination without administration of a booster dose of pertussis.
Pri spremljanju iste kohorte je bila učinkovitost potrjena do 60. meseca po popolnem osnovnem cepljenju, kateremu ni sledil obnovitveni odmerek proti oslovskemu kašlju.
Vaccinees with a history of febrile convulsions should be closely followed up as such adverse events may occur within 2 to 3 days
Cepljene osebe z anamnezo vročinskih krčev je treba natančno spremljati, kajti takšni neželeni dogodki se lahko pojavjio v 2 do 3 dneh po cepljenju.
There may be circumstances, such as a high incidence of pertussis, when the potential benefits outweigh possible risks.
V nekaterih okoliščinah, kot je visoka incidenca oslovskega kašlja, lahko pričakovana korist cepljenja prevlada nad možnim tveganjem.
There should be an interval of at least 1 month between doses.
Presledek med odmerki mora biti vsaj 1 mesec.
• Infanrix Penta is available in packs of 1, 10, 20 and 50 with or without needles.
• Cepivo Infanrix Penta je na voljo v pakiranjih po 1, 10, 20 in 50 injekcijskih brizg z injekcijskimi iglami ali brez njih.
As with other vaccines, it may be expected that in patients receiving immunosuppressive therapy an adequate response may not be achieved.
Kot pri drugih cepivih lahko tudi pri tem pričakujete, da pri bolnikih ki prejemajo imunosupresivno terapijo ne bo dosežen zadosten odziv na cepljenje.
2produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology 3adsorbed on aluminium phosphate (AlPO4)
2pridobljen s tehnologijo rekombinantne DNA na celični kulturi Saccharomyces cerevisiae 3adsorbiran na aluminijev fosfat (AlPO4)
Protective antibodies against hepatitis B have been shown to persist for at least 3.5 years in more than 90% of children administered four doses of a combined vaccine containing the same HBs antigen as Infanrix Penta.
Zaščitna protitelesa proti hepatitisu B so dokazano prisotna vsaj še 3,5 leta pri več kot 90 % otrok, ki dobijo štiri odmerke kombiniranega cepiva z enakim antigenom HBs, kot ga vsebuje Infanrix Penta.
months N=554
mesecev n =554
• Collapse or shock-like state (hypotonic-hyporesponsiveness episode) within 48 hours of vaccination;
• Kolaps ali šoku podobno stanje (hipotonična-hiporesponzivna epizoda) v 48 urah po cepljenju.
Important information about some of the ingredients of Infanrix Penta This vaccine contains neomycin and polymyxin (antibiotics).
Pomembne informacije o nekaterih sestavinah cepiva Infanrix Penta To cepivo vsebuje neomicin in polimiksin (antibiotika).
• Do not use Infanrix Penta after the expiry date which is stated on the carton.
• Cepiva Infanrix Penta ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli.
The other ingredients in Infanrix Penta are: sodium chloride (NaCl), medium 199 containing principally amino acids, mineral salts, vitamins and water for injections.
Druge sestavine cepiva Infanrix Penta so: natrijev klorid (NaCl), medij 199, ki vsebuje predvsem aminokisline, mineralne soli, vitamine in voda za injekcije.
As the immune response to pertussis antigens following Infanrix Penta administration is equivalent to that of Infanrix, the protective efficacy of the two vaccines is expected to be equivalent.
Ker je imunski odziv na antigen pertusisa po uporabi cepiva Infanrix Penta enak kot po uporabi cepiva Infanrix, je pričakovati, da bo zaščitni učinek obeh cepiv enak.
Wounds that are more likely to get tetanus infection are burns, fractures, deep wounds or wounds that have soil, dust, horse manure or wood splinters in them.
Rane, ki se še posebno rade okužijo s tetanusom so opekline, zlomi, globoke rane ali rane onesnažene z zemljo, s prahom, konjskimi iztrebki ali lesenimi trskami.
6.6 Special precautions for disposal and other handling Upon storage, a white deposit and clear supernatant may be observed.
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom Med shranjevanjem se lahko pojavi bela usedlina in bister supernatant.
Very rare: convulsions (with or without fever) Respiratory, thoracic and mediastinal disorders
Zelo redki: konvulzije (s povišano telesno temperaturo ali brez nje) Bolezni dihal, prsnega koša in mediastinalnega prostora
• your child has had problems of the nervous system within 7 days after previous vaccination with a vaccine against whooping cough.
• je imel težave z živčevjem v prvih 7 dneh po cepljenju s cepivom proti oslovskemu kašlju;
• If your child misses an injection which is due, it is important that you make another appointment.
• Če vaš otrok zamudi predvideni odmerek, je pomembno, da ga prenaročite.
• Whooping cough (Pertussis) - a highly infectious illness that affects the airways.
• Oslovski kašelj (pertusis) - zelo nalezljiva bolezen, ki prizadane dihalne poti.